Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LXRX Lexicon Pharmaceuticals

Market Closed 12-12 16:00:00 EST

1.30

-0.02

-1.52%

盘后1.31

+0.01+0.77%

19:58 EST

High1.35	Low1.30	Vol1.08M
Open1.32	D1 Closing1.32	Amplitude3.79%
Mkt Cap472.42M	Tradable Cap239.06M	Total Shares363.40M
T/O1.43M	T/O Rate0.59%	Tradable Shares183.89M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LXRX","market":"US","secType":"STK","nameCN":"Lexicon Pharmaceuticals","latestPrice":1.3,"timestamp":1765573200000,"preClose":1.32,"halted":0,"volume":1080696,"hourTrading":{"tag":"盘后","latestPrice":1.31,"preClose":1.3,"latestTime":"19:58 EST","volume":40574,"amount":52762.2195,"timestamp":1765587516327},"delay":0,"floatShares":183889453,"shares":363398680,"eps":-0.189102,"marketStatus":"Market Closed","change":-0.02,"latestTime":"12-12 16:00:00 EST","open":1.32,"high":1.35,"low":1.3,"amount":1431973.9653383999,"amplitude":0.037879,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.189102,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":955080000000,"exchange":"NASDAQ","adjPreClose":1.32,"preHourTrading":{"tag":"盘前","latestPrice":1.33,"preClose":1.32,"latestTime":"09:27 EST","volume":229,"amount":299.6519502,"timestamp":1765549670052},"postHourTrading":{"tag":"盘后","latestPrice":1.31,"preClose":1.3,"latestTime":"19:58 EST","volume":40574,"amount":52762.2195,"timestamp":1765587516327},"volumeRatio":0.6784392988377993,"impliedVol":1.4487,"impliedVolPercentile":0.476},"requestUrl":"/m/hq/s/LXRX/wiki","defaultTab":"wiki","newsList":[{"id":"2590587065","title":"Lexicon Pharmaceuticals Signs Exclusive Global Licensing Agreement for LX9851 with Novo Nordisk","url":"https://stock-news.laohu8.com/highlight/detail?id=2590587065","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590587065?lang=en_us&edition=fundamental","pubTime":"2025-12-10 21:30","pubTimestamp":1765373416,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals Inc. announced that in March 2025, it entered into an exclusive, worldwide licensing agreement for LX9851 with Novo Nordisk. The agreement covers LX9851, an investigational non-incretin, oral, small molecule ACSL5 inhibitor being developed for obesity and chronic weight management.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on December 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL27QbFm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4139","SG9999014013.SGD","SG9999014021.USD","LU2095319765.USD","LU0314104364.USD","BK4585","BK4588","LU2210149790.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014005.SGD","LU2210150020.SGD","BK4007","IE00BKPKM429.USD","SG9999014039.USD","LXRX","NDAQ","BK4112"],"gpt_icon":1},{"id":"2590580761","title":"Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851","url":"https://stock-news.laohu8.com/highlight/detail?id=2590580761","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590580761?lang=en_us&edition=fundamental","pubTime":"2025-12-10 21:30","pubTimestamp":1765373400,"startTime":"0","endTime":"0","summary":"THE WOODLANDS, Texas, Dec.  10, 2025  (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.(Nasdaq: LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as a ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/10/3203150/0/en/Lexicon-Pharmaceuticals-Announces-Publication-of-Preclinical-Data-in-the-Journal-of-the-Endocrine-Society-on-Acyl-CoA-Synthetase-5-ACSL5-Reinforcing-the-Scientific-Rationale-for-LX.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","LXRX"],"gpt_icon":0},{"id":"2589689063","title":"Lexicon Pharmaceuticals to Present New Sotagliflozin Data on Adipose Distribution in Non-Diabetic HFpEF Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2589689063","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589689063?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:30","pubTimestamp":1764941412,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals Inc. announced that clinical data on the effect of sotagliflozin on adipose tissue distribution in non-diabetic patients will be presented at the 22nd Global Cardio Vascular Clinical Trialists Forum , scheduled for December 8-10, 2025, in Washington, D.C. The data are derived from the SOTA-P-CARDIA trial, a prospective, randomized, double-blind, placebo-controlled study enrolling patients with heart failure with preserved ejection fraction  and conducted by Mount Sinai Medical Center. The presentation, titled \"Effect of sotagliflozin on adipose distribution in non-diabetic patients with HFpEF,\" will be delivered by Juan Jose Badimon, Ph.D., on December 8, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL8lCL7T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2210150020.SGD","LU2095319765.USD","BK4007","IE00BGHQF748.EUR","BK4588","IE00BKPKM429.USD","LXRX","NDAQ","LU2210149790.SGD","BK4585","BK4112","BK4139"],"gpt_icon":0},{"id":"2586475460","title":"Lexicon Pharmaceuticals to Present at Piper Sandler and Evercore Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2586475460","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586475460?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:30","pubTimestamp":1764077415,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals Inc. will participate in two upcoming investor conferences in December. The company is scheduled for a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3 at 9:00 a.m. ET, and will also attend the 8th Annual Evercore Healthcare Conference on Thursday, December 4 at 9:10 a.m. ET. Live events and replays of the presentations will be available on the Events page of the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on November 25, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL75Y0dK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B64PRP62.GBP","LXRX","EVR","LU2210150020.SGD","IE00BGHQF748.EUR","NDAQ","LU2210149790.SGD","BK4588","PIPR","BK4127","LU2095319765.USD","BK4585","IE00B3QW5Z07.USD","BK4139","BK4007","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2584578929","title":"Lexicon Pharmaceuticals Inc Files For Offering Of Up To $75 Million Of Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584578929","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584578929?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:00","pubTimestamp":1763571626,"startTime":"0","endTime":"0","summary":"Nov 7 (Reuters) - Lexicon Pharmaceuticals Inc ::*LEXICON PHARMACEUTICALS INC FILES FOR OFFERING OF UP TO $75 MILLION OF COMMON STOCK - SEC FILING  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202523:07:41 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSDbjqp58:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","LXRX"],"gpt_icon":0},{"id":"2584926732","title":"Lexicon Pharmaceuticals Q3 EPS USD -0.04","url":"https://stock-news.laohu8.com/highlight/detail?id=2584926732","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584926732?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:53","pubTimestamp":1763571220,"startTime":"0","endTime":"0","summary":"Nov 06 (Reuters) - Lexicon Pharmaceuticals Q3 basic EPS USD -0.04.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202512:00:09.673 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD6G2Z7p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","BK4007","BK4139"],"gpt_icon":0},{"id":"1112567484","title":"Stock Track | Lexicon Pharmaceuticals Surges 5.28% on Upcoming Jefferies Conference Participation","url":"https://stock-news.laohu8.com/highlight/detail?id=1112567484","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112567484?lang=en_us&edition=fundamental","pubTime":"2025-11-12 00:04","pubTimestamp":1762877075,"startTime":"0","endTime":"0","summary":"Shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) are soaring 5.28% during Tuesday's intraday trading session, following the company's announcement of its participation in the prestigious Jefferies...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["LXRX"],"gpt_icon":0},{"id":"1179883925","title":"Stock Track | Lexicon Pharmaceuticals Soars 5.28% on Upcoming Jefferies Conference Participation","url":"https://stock-news.laohu8.com/highlight/detail?id=1179883925","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179883925?lang=en_us&edition=fundamental","pubTime":"2025-11-12 00:02","pubTimestamp":1762876958,"startTime":"0","endTime":"0","summary":"Shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) are soaring 5.28% during Tuesday's intraday trading session, following the announcement of the company's participation in the upcoming Jefferies 2025...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["LXRX"],"gpt_icon":0},{"id":"2582361004","title":"Lexicon Pharmaceuticals to Join Jefferies London Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2582361004","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582361004?lang=en_us&edition=fundamental","pubTime":"2025-11-11 21:30","pubTimestamp":1762867814,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals Inc. will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on November 18, 2025. The event will be available via the Events page on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on November 11, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nNDL6Ng8Pt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU0314104364.USD","BK4139","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4588","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","LU2210150020.SGD","BK4007","LXRX","NDAQ","LU2095319765.USD","BK4112"],"gpt_icon":0},{"id":"2582817000","title":"Lexicon Study Finds Sotagliflozin Improves Outcomes in HFpEF Patients Without Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2582817000","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582817000?lang=en_us&edition=fundamental","pubTime":"2025-11-10 10:08","pubTimestamp":1762740538,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals Inc. has announced new clinical data from a study evaluating sotagliflozin in patients with heart failure with preserved ejection fraction  without diabetes. The results were presented at the American Heart Association  Annual Scientific Sessions 2025. The randomized, double-blind, placebo-controlled trial, conducted under the direction of Dr. Juan J Badimon at Mount Sinai Medical Center, enrolled 88 racially diverse participants, 70 percent of whom were female. Over a six-month treatment period, patients receiving sotagliflozin demonstrated statistically significant improvements in left ventricular mass, diastolic function, six-minute walk test performance, and Kansas City Cardiomyopathy Questionnaire  scores compared to placebo. While peak VO2 improvement was not statistically significant, a notable trend was observed. This study is reported as the first to demonstrate clinical benefits of sotagliflozin for HFpEF patients without diabetes.Disclaimer: This news","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL9rNgNP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2210149790.SGD","LU2210150020.SGD","BK4588","LXRX","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","BK4585","BK4139","IE00BKPKM429.USD","BK4007","NDAQ","BK4112","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2582093818","title":"Lexicon announces new sotagliflozin clinical data at AHA Sessions 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2582093818","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582093818?lang=en_us&edition=fundamental","pubTime":"2025-11-10 02:20","pubTimestamp":1762712408,"startTime":"0","endTime":"0","summary":"Lexicon (LXRX) Pharmaceuticals announced that new sotagliflozin clinical data was presented at the American Heart Association, AHA, Annual Scientif...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexicon-announces-new-sotagliflozin-clinical-data-at-aha-sessions-2025-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexicon-announces-new-sotagliflozin-clinical-data-at-aha-sessions-2025-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXRX","BK4007","BK4139"],"gpt_icon":0},{"id":"1199143082","title":"Stock Track | Lexicon Pharmaceuticals Plummets 5.24% Pre-Market on $75 Million Stock Offering News","url":"https://stock-news.laohu8.com/highlight/detail?id=1199143082","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199143082?lang=en_us&edition=fundamental","pubTime":"2025-11-07 23:10","pubTimestamp":1762528207,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals (LXRX) shares tumbled 5.24% in pre-market trading on Friday, following the company's announcement of a new stock offering. The biopharmaceutical firm's stock price reacted...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["LXRX"],"gpt_icon":0},{"id":"1171517226","title":"Stock Track | Lexicon Pharmaceuticals Plummets 5.24% Following $75 Million Stock Offering Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=1171517226","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171517226?lang=en_us&edition=fundamental","pubTime":"2025-11-07 23:09","pubTimestamp":1762528172,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals (LXRX) saw its stock price plummet 5.24% in Friday's pre-market trading session, following the company's announcement of a new stock offering. The sharp decline reflects...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["LXRX"],"gpt_icon":0},{"id":"1172714488","title":"Stock Track | Lexicon Pharmaceuticals Plunges 7.69% on $75 Million Stock Offering Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=1172714488","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172714488?lang=en_us&edition=fundamental","pubTime":"2025-11-07 15:28","pubTimestamp":1762500518,"startTime":"0","endTime":"0","summary":"Shares of Lexicon Pharmaceuticals (LXRX) experienced a significant downturn in Friday's trading session, plummeting 7.69% following the company's announcement of a new stock offering. The sharp...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["LXRX"],"gpt_icon":0},{"id":"2581044824","title":"BRIEF-Lexicon Pharmaceuticals Inc Files For Offering Of Up To $75 Million Of Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2581044824","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581044824?lang=en_us&edition=fundamental","pubTime":"2025-11-07 07:07","pubTimestamp":1762470461,"startTime":"0","endTime":"0","summary":"BRIEF-Lexicon Pharmaceuticals Inc Files For Offering Of Up To $75 Million Of Common Stock - SEC FilingNov 7  - Lexicon Pharmaceuticals Inc LXRX.O:LEXICON PHARMACEUTICALS INC FILES FOR OFFERING OF UP TO $75 MILLION OF COMMON STOCK - SEC FILINGSource text: [ID:n0001193125-25-270167]Further company coverage: LXRX.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nFWN3WI1RN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXRX"],"gpt_icon":0},{"id":"2581404121","title":"Lexicon Pharmaceuticals Files Prospectus for Stock Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2581404121","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581404121?lang=en_us&edition=fundamental","pubTime":"2025-11-07 06:52","pubTimestamp":1762469571,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals ( ($LXRX) ) has issued an update. On November 6, 2025, Lexicon Pharmaceuticals filed a prospectus supplement related to its...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lexicon-pharmaceuticals-files-prospectus-for-stock-sale?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lexicon-pharmaceuticals-files-prospectus-for-stock-sale?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXRX","BK4139"],"gpt_icon":0},{"id":"2581049254","title":"Lexicon Pharmaceuticals Inc Files for Offering of up to $75 Mln of Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2581049254","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581049254?lang=en_us&edition=fundamental","pubTime":"2025-11-07 06:31","pubTimestamp":1762468286,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nFWN3WI1RN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LXRX","BK4139"],"gpt_icon":0},{"id":"2581013520","title":"Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR), Lexicon Pharmaceuticals (LXRX) and Cullinan Management (CGEM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581013520","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581013520?lang=en_us&edition=fundamental","pubTime":"2025-11-07 00:50","pubTimestamp":1762447815,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Schrodinger (SDGR – Research Report), Lexicon Pharmaceuticals (LX...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-schrodinger-sdgr-lexicon-pharmaceuticals-lxrx-and-cullinan-management-cgem-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-schrodinger-sdgr-lexicon-pharmaceuticals-lxrx-and-cullinan-management-cgem-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1046422090.SGD","LU1235295612.USD","LX","HCSG","XBI","SDGR","CGEM","LXRX","BK4137","LU0049112450.USD","XLV","LABU","BK4581","BK4588","LU0128526141.USD","BK4531","BK4166","BK4585","BK4139","LU0029874061.USD","BK4579","BK4167"],"gpt_icon":0},{"id":"1111463697","title":"Stock Track | Lexicon Pharmaceuticals Soars 5.05% on Better-Than-Expected Q3 Results and Revenue Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=1111463697","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111463697?lang=en_us&edition=fundamental","pubTime":"2025-11-07 00:04","pubTimestamp":1762445067,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals (NASDAQ:LXRX) stock is soaring 5.05% in pre-market trading on Thursday following the release of its third-quarter 2025 financial results, which surpassed analysts'...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["LXRX"],"gpt_icon":0},{"id":"2581024060","title":"Lexicon Pharma Q3 net loss narrows as R&D costs drops","url":"https://stock-news.laohu8.com/highlight/detail?id=2581024060","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581024060?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:39","pubTimestamp":1762432771,"startTime":"0","endTime":"0","summary":"Lexicon Pharma Q3 net loss narrows as R&D costs dropsOverviewLexicon Q3 2025 total revenue increased to $14.2 mln, driven by licensing revenueNet loss for Q3 2025 was $12.8 mln, significantly lower th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0O8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lexpharma.com","stockEarnings":[{"period":"1week","weight":-0.0714},{"period":"1month","weight":-0.1558},{"period":"3month","weight":0.1304},{"period":"6month","weight":0.936},{"period":"1year","weight":0.5811},{"period":"ytd","weight":0.7603}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.52,"avgChangeRate":0.042172},{"month":2,"riseRate":0.4,"avgChangeRate":-0.059177},{"month":3,"riseRate":0.48,"avgChangeRate":-0.019425},{"month":4,"riseRate":0.44,"avgChangeRate":0.012763},{"month":5,"riseRate":0.5,"avgChangeRate":0.029091},{"month":6,"riseRate":0.653846,"avgChangeRate":0.134775},{"month":7,"riseRate":0.5,"avgChangeRate":0.021487},{"month":8,"riseRate":0.269231,"avgChangeRate":-0.025279},{"month":9,"riseRate":0.346154,"avgChangeRate":0.011129},{"month":10,"riseRate":0.538462,"avgChangeRate":-0.006481},{"month":11,"riseRate":0.384615,"avgChangeRate":-0.041818},{"month":12,"riseRate":0.461538,"avgChangeRate":0.066192}],"exchange":"NASDAQ","name":"Lexicon Pharmaceuticals","nameEN":"Lexicon Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lexicon Pharmaceuticals(LXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lexicon Pharmaceuticals,LXRX,Lexicon Pharmaceuticals股票,Lexicon Pharmaceuticals股票老虎,Lexicon Pharmaceuticals股票老虎国际,Lexicon Pharmaceuticals行情,Lexicon Pharmaceuticals股票行情,Lexicon Pharmaceuticals股价,Lexicon Pharmaceuticals股市,Lexicon Pharmaceuticals股票价格,Lexicon Pharmaceuticals股票交易,Lexicon Pharmaceuticals股票购买,Lexicon Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lexicon Pharmaceuticals(LXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction